Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Pediatr Cardiol ; 45(1): 150-155, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37870602

ABSTRACT

Postoperative chylothorax in patients with congenital heart diseases (CHD) results in poor outcomes if anatomical and functional abnormalities of the lymphatic system are present. While these abnormalities are typically diagnosed by intranodal lymphangiography and dynamic contrast magnetic resonance lymphangiography, the usefulness of lymphoscintigraphy in these patients has not been evaluated. Between January 2019 and December 2021, 28 lymphoscintigraphies were performed in our institution for investigating prolonged pleural effusion after cardiac surgery. The images were assessed by three board-certified pediatric cardiologists retrospectively to determine the likelihood of a central lymphatic flow disorder. The likelihood was scored (range 1-3) based on structural abnormalities and congestive flow in the lymphatic system. Those scores were summed and the likelihood was categorized as low to intermediate (< 8 points) or high (8 or 9 points). Median age at lymphoscintigraphy was 129 days (IQR, 41-412 days), it was performed at a median of 22 days (IQR, 17-43) after surgery, and median score was 6 points (IQR, 4-7.5). Kendall's coefficient of concordance (0.867; p < 0.05) indicated high inter-rater reliability. Overall survival at 6 months after surgery was 92.5% in the low-to-intermediate group but 68.6% in the high group (p < 0.05), and duration of postoperative thoracic drainage was 27 and 58 days, respectively (p < 0.05). Lymphatic abnormalities detected by lymphoscintigraphy were associated with poorer outcomes. Lymphoscintigraphy was thought to be useful in assessing anatomic and functional lymphatic abnormalities, despite its minimal invasiveness.


Subject(s)
Cardiac Surgical Procedures , Chylothorax , Lymphatic Abnormalities , Child , Humans , Chylothorax/diagnostic imaging , Chylothorax/etiology , Lymphoscintigraphy , Retrospective Studies , Reproducibility of Results , Cardiac Surgical Procedures/adverse effects , Lymphography/methods
2.
Hum Genome Var ; 10(1): 25, 2023 Sep 11.
Article in English | MEDLINE | ID: mdl-37696855

ABSTRACT

Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by brittle bones. In this case report, we describe a patient who suffered from OI type XIV with a novel splice site variant in the TMEM38B gene. Further research is needed to better understand the relationship between the phenotype of OI type XIV and this variant.

3.
Pediatr Cardiol ; 43(7): 1653-1658, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35562506

ABSTRACT

Recently, the outcome of severe Ebstein anomaly (EA) has improved with the prevalence of the Starnes procedure. However, time-dependent changes in the size of the central pulmonary artery (PA) have not been fully understood. A retrospective chart review of patients with EA who underwent the Starnes procedure during the neonatal period and those with pulmonary atresia with intact ventricular septum (PAIVS) was performed at Fukuoka Children's Hospital. There were 14 patients in the severe EA group and 36 in the PAIVS group, with mean observational periods of 3.8 and 4.2 years, respectively. No significant difference in survival was observed between the groups. However, the mean size of the central PA was smaller in the severe EA group at each surgical stage (after systemic-to-pulmonary shunt, after the bidirectional Glenn procedure, and after the Fontan procedure). A significantly larger ventricular volume was observed in the severe EA group after the Fontan procedure. The growth of the central PA was poor in patients with severe EA. Patients with severe EA should be carefully monitored in this regard both before and after undergoing the Fontan procedure. Further studies regarding long-term prognosis are expected.


Subject(s)
Ebstein Anomaly , Fontan Procedure , Pulmonary Atresia , Child , Ebstein Anomaly/surgery , Humans , Infant , Infant, Newborn , Pulmonary Artery/surgery , Pulmonary Atresia/surgery , Retrospective Studies , Treatment Outcome
4.
Pediatr Cardiol ; 43(2): 360-365, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34498105

ABSTRACT

Patients with Down's syndrome (DS) are generally regarded as not being good candidates for the Fontan procedure. However, detailed hemodynamic changes over time are not fully clarified. A retrospective chart review of all patients with DS who underwent the Fontan procedure and 5 times that number of Fontan patients without DS performed in Fukuoka Children's Hospital and Kyushu University Hospital. Seven Fontan patients with DS were identified, and 35 Fontan patients without DS were recruited. During the mean observational periods of 14.7 years and 15.0 years (DS and non-DS, respectively) after the Fontan procedure, only one DS patient died. Central venous pressure (CVP) and transpulmonary pressure gradient significantly increased, and arterial oxygen saturation significantly decreased over time in DS patients after the Fontan procedure compared with those without DS. CVP in DS patients after the Fontan procedure increased over time compared with non-DS patients. Better management including the efficacy of Pulmonary arterial hypertension-specific therapy should be clarified in further studies.


Subject(s)
Down Syndrome , Fontan Procedure , Heart Defects, Congenital , Central Venous Pressure , Child , Down Syndrome/complications , Heart Defects, Congenital/surgery , Hemodynamics , Humans , Retrospective Studies
5.
Int Heart J ; 62(3): 559-565, 2021 May 29.
Article in English | MEDLINE | ID: mdl-33994500

ABSTRACT

An intractable pleural effusion is a common comorbidity of a Fontan operation, occasionally leading to undesirable outcomes. The preventive effect of aortopulmonary collateral (APC) coil embolization against a pleural effusion before a Fontan operation is still controversial.This is a retrospective single-center study; among 227 Fontan cases, 57 cases with complete MRI data were analyzed at first. Factors associated with the duration of pleural drainage (median: 6 (2-41) days) and that of postoperative hospital stay (median: 25 (14-91) days) were analyzed using a multiple regression analysis. The pulmonary artery index (PAI; Nakata index) was associated with both the pleural drainage duration (P < 0.05, r2 = 0.17) and postoperative hospital stay (P < 0.05, r2 = 0.10).Thereafter, all the 227 patients were classified into the following three groups: Group A (12 patients in whom the embolization was performed within 30 days before the Fontan surgery), Group B (131 patients in whom the embolization was performed more than 30 days before the Fontan surgery), and Group C (84 patients in whom the embolization was not performed). Patients in Group A were found to be associated with the shortest length of both periods (P < 0.05).Lower PAI values were related to a prolonged pleural drainage duration and postoperative hospital stay. APC coil embolizations may reduce the risk if they are performed shortly (less than 30 days) before the operation.


Subject(s)
Embolization, Therapeutic , Fontan Procedure/adverse effects , Pleural Effusion/prevention & control , Postoperative Complications/prevention & control , Child, Preschool , Female , Humans , Male , Pleural Effusion/etiology , Postoperative Complications/etiology , Retrospective Studies , Risk Factors
7.
Pediatr Cardiol ; 41(8): 1800-1806, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32915292

ABSTRACT

In the Fontan circulation, there is a substantial degree of systemic-to-pulmonary collateral flow (SPCF), which can be measured by cardiac magnetic resonance (CMR). However, the correlation between the degree of SPCF and long-term outcomes is not fully understood. We retrospectively studied 321 patients who underwent the Fontan procedure and CMR at a single center. Using CMR, we calculated SPCF as pulmonary blood flow - systemic blood flow. %SPCF was defined as SPCF ÷ pulmonary blood flow. The mean age of patients at CMR was 14.3 ± 7.5 years. The average %SPCF was 13.0% ± 11.0%. With a multivariate analysis, %SPCF was significantly correlated with time (i.e., the longer the time period since the Fontan procedure, the lower the %SPCF) (p = 0.006), previous total anomalous pulmonary vein drainage (p = 0.007), a low pulmonary artery index (Nakata index) before the Fontan procedure (p = 0.04), and older age at the time of the Fontan procedure (p = 0.002). Regarding the findings after the Fontan procedure, %SPCF was significantly correlated with ventricular end-diastolic volume (p < 0.001), ventricular end-systolic volume (p < 0.001), central venous pressure (p < 0.001), plasma brain natriuretic peptide concentration (p < 0.001), hemoptysis (p = 0.009), and poor New York Heart Association functional class (p = 0.007). SPCF was correlated with clinical condition after the Fontan procedure. The importance of sufficient growth of the pulmonary vascular bed should be emphasized because the development of SPCF is believed to result from the poor condition of the pulmonary circulation.


Subject(s)
Fontan Procedure/methods , Heart Defects, Congenital/surgery , Pulmonary Circulation , Adolescent , Blood Flow Velocity , Child , Female , Heart Defects, Congenital/physiopathology , Heart Ventricles/physiopathology , Hemoptysis , Humans , Magnetic Resonance Imaging , Male , Multivariate Analysis , Pulmonary Artery/physiopathology , Retrospective Studies , Stroke Volume , Young Adult
8.
Heart Rhythm ; 16(12): 1870-1874, 2019 12.
Article in English | MEDLINE | ID: mdl-31252085

ABSTRACT

BACKGROUND: Pacemaker implantation in patients with single ventricle is associated with poor outcomes. OBJECTIVE: The purpose of this study was to determine the reasons for the poor outcomes of pacemaker implantation. METHODS: We performed a retrospective chart review of patients with single ventricle who had undergone permanent pacemaker implantation. Patients were categorized into 3 groups based on the site of pacing and the proportion of ventricular pacing (VP) as follows: (1) atrial pacing group with atrial pacing only (n = 11); (2) low VP group with low daily VP proportion (<50%; n = 12); and (3) high VP group with high daily VP proportion (≥50%; n = 15). Pacing leads were placed at the epicardium in all patients. RESULTS: No patients in the atrial pacing or low VP groups died, whereas the survival rate in the high VP group was 58.9% and 39.3% at 10 and 20 years, respectively, after pacemaker implantation. Among the post-Fontan patients, plasma brain natriuretic peptide (BNP) levels significantly increased with the proportion of VP: 11.7, 20.3, and 28.4 pg/mL in the atrial pacing, low VP, and high VP groups, respectively (P = 0.04). In the high VP group, the plasma BNP level was significantly lower in patients with an apical pacing lead than in those with a nonapical pacing lead (27.0 pg/mL vs 82.8 pg/mL, respectively; P = .03). CONCLUSION: A higher proportion of VP was associated with poor outcome and higher plasma BNP levels, probably due to ventricular dyssynchrony. In epicardial ventricular pacing, apical pacing is better to avoid the increase in ventricular stress and plasma BNP level.


Subject(s)
Cardiac Pacing, Artificial , Natriuretic Peptide, Brain/blood , Stroke Volume , Univentricular Heart , Adult , Cardiac Pacing, Artificial/adverse effects , Cardiac Pacing, Artificial/methods , Female , Fontan Procedure/methods , Heart Atria/physiopathology , Humans , Male , Outcome and Process Assessment, Health Care , Pacemaker, Artificial/adverse effects , Survival Rate , Univentricular Heart/blood , Univentricular Heart/mortality , Univentricular Heart/physiopathology , Univentricular Heart/therapy
9.
Circ J ; 83(6): 1338-1341, 2019 05 24.
Article in English | MEDLINE | ID: mdl-31019158

ABSTRACT

BACKGROUND: Liver stiffness on ultrasound shear-wave elastography (SWE) reflects central venous pressure (CVP) in adult patients with heart failure, but the association of liver stiffness on SWE with CVP in pediatric patients is not clear. The present study evaluated whether liver stiffness on SWE is useful as a non-invasive indicator of CVP in pediatric patients.Methods and Results:Liver stiffness was measured using ultrasound SWE in 79 patients aged <20 years with congenital heart diseases. None of the patients was found to have liver disease. Correlations between liver stiffness and other clinical variables, including CVP, were analyzed. CVP was the only factor independently and significantly correlated with liver stiffness in multivariate analysis. However, variables related to hepatic fibrosis did not correlate with liver stiffness. CONCLUSIONS: Liver stiffness on ultrasound SWE is useful as a non-invasive indicator of CVP in children with heart diseases.


Subject(s)
Elasticity Imaging Techniques , Heart Defects, Congenital , Liver , Venous Pressure , Adolescent , Child , Female , Heart Defects, Congenital/diagnostic imaging , Heart Defects, Congenital/physiopathology , Humans , Liver/diagnostic imaging , Liver/parasitology , Male
10.
Pediatr Cardiol ; 39(7): 1339-1345, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29785512

ABSTRACT

The exercise tolerance of Fontan patients is poorer than that of healthy people. Some previous studies reported that exercise tolerance can be improved in this population by cardiac rehabilitation. This study aimed to determine the factors associated with peak oxygen uptake (VO2) and to subsequently clarify the correlation between participation in sports club activities and variables related to exercise tolerance. Cardiopulmonary exercise tests were performed by 115 Fontan patients aged between 6 and 20 years. The patients completed questionnaires on their daily physical activities including participation in extracurricular sports clubs in middle (junior high school) and high school. Peak VO2 had a significant negative correlation with age and a positive correlation with hemoglobin, stroke volume, and resting tidal volume in the entire study group. Additionally, the sports club participants who were middle and high school students had significantly higher peak VO2 and resting tidal volume. Exercise habits including participation in sports club activities may promote exercise tolerance by improving respiratory function in Fontan adolescents.


Subject(s)
Exercise Tolerance/physiology , Fontan Procedure/methods , Oxygen Consumption/physiology , Sports/physiology , Adolescent , Adult , Asian People , Child , Exercise/physiology , Exercise Test/methods , Female , Fontan Procedure/adverse effects , Humans , Male , Respiratory Function Tests/methods , Schools , Students , Young Adult
13.
Int J Cardiol ; 205: 37-42, 2016 Feb 15.
Article in English | MEDLINE | ID: mdl-26710331

ABSTRACT

BACKGROUND: Tolvaptan, a vasopressin V2-receptor antagonist, has been reported to improve congestion in adult patients with heart failure. However, it has not been fully clarified whether tolvaptan is also effective and safe for pediatric patients as well as adult. METHODS: This trial was a multicenter, retrospective, observational study, and was led by the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH). Thirty-four pediatric patients who received tolvaptan to treat congestive heart failure were enrolled in this study. RESULTS: An increment in the urinary volume and decrease in the body weight from baseline were significant at day 1 (+106.7 ± 241.5%, p = 0.008 and -2.30 ± 4.17%, p = 0.01), day 3 (+113.5 ± 261.9%, p = 0.02 and -2.30 ± 4.17%, p = 0.01), week 1 (+56.3 ± 163.5%, p = 0.01 and -1.55 ± 4.09%, p = 0.03) and month 1 (+91.1 ± 171.6%, p = 0.01 and -2.95 ± 5.98, p = 0.03). The significant predictive factors in responders, who was defined as patients who achieved an increase in the urinary volume at day 1, were older age (p = 0.03), larger body weight before exacerbation (p = 0.04), higher weight at one day before the first administration of tolvaptan (p = 0.03), higher aspartate aminotransferase levels (p = 0.03) and higher urinary osmolality levels (p = 0.03). A logistic regression analysis showed that the urinary osmolality was the only significant predictive factor for responders to tolvaptan. Adverse drug reactions were observed in 7 patients (20.6%). Six patients had thirst and a dry month, and 1 had a mild increase in the alanine aminotransferase and aspartate aminotransferase. CONCLUSION: Tolvaptan can be effectively and safely administered in pediatric patients. Because the kidneys in neonates and infants are resistant to arginine vasopressin, the efficacy of tolvaptan may be less effective compared to older children.


Subject(s)
Antidiuretic Hormone Receptor Antagonists/therapeutic use , Benzazepines/therapeutic use , Coronary Circulation/drug effects , Heart Failure/drug therapy , Hemodynamics/drug effects , Societies, Medical , Adolescent , Antidiuretic Hormone Receptor Antagonists/adverse effects , Antidiuretic Hormone Receptor Antagonists/pharmacology , Benzazepines/adverse effects , Benzazepines/pharmacology , Blood Circulation/drug effects , Blood Circulation/physiology , Child , Child, Preschool , Coronary Circulation/physiology , Female , Heart Failure/epidemiology , Heart Failure/physiopathology , Hemodynamics/physiology , Humans , Infant , Japan/epidemiology , Male , Pediatrics/methods , Retrospective Studies , Surveys and Questionnaires , Tolvaptan , Treatment Outcome
14.
Heart Lung ; 44(5): 451-2, 2015.
Article in English | MEDLINE | ID: mdl-26138776

ABSTRACT

A diffuse patchy pattern in the perfusion scan of the lung is a hallmark of severe pulmonary arterial hypertension (PAH). However, the mechanisms of this unique pattern remain uncertain. We here present the case of a 19-year-old woman with severe PAH who demonstrated reversal of the diffuse patchy pattern with improvement of pulmonary blood flow within a month after upfront triple combination therapy. Our case is a first report showing reversibility of diffuse patchy pattern by a short-term treatment in severe PAH. These findings suggest the possibility that the mechanisms underlying the diffuse patchy pattern may involve reversible vasoconstriction in addition to remodeling of small pulmonary arteries.


Subject(s)
Antihypertensive Agents/therapeutic use , Hypertension, Pulmonary/diagnostic imaging , Hypertension, Pulmonary/drug therapy , Lung/diagnostic imaging , Adult , Bosentan , Drug Therapy, Combination , Epoprostenol/therapeutic use , Female , Humans , Hypertension, Pulmonary/physiopathology , Pulmonary Circulation , Radiography , Radionuclide Imaging , Sulfonamides/therapeutic use , Tadalafil/therapeutic use
15.
Pediatr Int ; 54(6): 923-6, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23279022

ABSTRACT

The case is described herein of a patient with alveolar capillary dysplasia with double-outlet right ventricle and duodenal atresia who survived for a remarkably long time. The newborn girl was born at a gestational age of 36 weeks and weighed 1926 g. One min after delivery the Apgar score was 4. The patient had persistent pulmonary hypertension (PH) and needed nitric oxide inhalation and i.v. epoprostenol all through her life. Although other oral medications for PH were tried, they could not be used in practice because of gastrointestinal complications. The patient died on the 237 th day of life as a result of worsening PH associated with infection.


Subject(s)
Epoprostenol/analogs & derivatives , Epoprostenol/therapeutic use , Nitric Oxide/administration & dosage , Persistent Fetal Circulation Syndrome/drug therapy , Piperazines/therapeutic use , Pulmonary Alveoli/abnormalities , Sulfonamides/therapeutic use , Sulfones/therapeutic use , Administration, Inhalation , Bosentan , Bronchodilator Agents/administration & dosage , Dose-Response Relationship, Drug , Drug Therapy, Combination , Epoprostenol/administration & dosage , Fatal Outcome , Female , Follow-Up Studies , Humans , Infant, Newborn , Persistent Fetal Circulation Syndrome/diagnosis , Persistent Fetal Circulation Syndrome/physiopathology , Piperazines/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/therapeutic use , Pulmonary Alveoli/physiopathology , Purines/administration & dosage , Purines/therapeutic use , Sildenafil Citrate , Sulfonamides/administration & dosage , Sulfones/administration & dosage , Time Factors , Vasodilator Agents/administration & dosage , Vasodilator Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...